Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
NeuHyll
San Diego, California, United Statesneuhyll.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
NeuHyll is an early-stage biotechnology company focused on developing innovative treatments for chronic neuropathic pain and neurodegenerative conditions. The company utilizes a proprietary platform that leverages modified hyaluronic acid (hyaluronan) to create localized, sustained-release delivery systems for neuro-active compounds. By targeting the microenvironment of damaged nerves and the central nervous system, NeuHyll aims to provide non-opioid alternatives for pain management and promote neural regeneration. Their research is centered on optimizing the interaction between therapeutic ligands and neural receptors to improve functional recovery in patients with spinal cord injuries and cognitive decline.
- Therapeutic areas
- Neurology
- Modalities
- Small moleculePeptideHydrogel-based drug delivery therapy
- Industry
- Biotech
Beyond the preview
Go deeper on NeuHyll.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NeuHyll.